Apuli Maricel, the Chief Accounting Officer of BridgeBio Pharma, Inc., has disclosed a stock transaction that occurred on November 16, 2026. This filing is significant as it highlights the ongoing practices surrounding employee compensation in the pharmaceutical industry.

Background

BridgeBio Pharma, Inc. is a company focused on developing innovative therapies for genetic diseases. It operates under the SIC classification of Pharmaceutical Preparations. The company has been active in the market, with recent filings indicating ongoing transactions and activities related to its stock.

What the Filing Says

According to the recent SEC filing, Apuli Maricel reported the acquisition of 4,714 shares of common stock, which were withheld to cover tax obligations related to the vesting of restricted stock units (RSUs). The transaction price was $77.36 per share, and following this transaction, Maricel owns a total of 115,973 shares of the company.

Impact

This transaction may influence various stakeholders, including investors and employees, as it reflects the company's approach to managing compensation and tax obligations. The filing also underscores the importance of transparency in financial reporting, especially in the pharmaceutical sector where regulatory scrutiny is high.

What's Next

The filing does not say what happens next.

Details of the Transaction

The filing indicates that the 4,714 shares acquired by Apuli Maricel were withheld specifically to cover tax obligations related to the vesting of 9,261 shares of Common Stock from restricted stock units (RSUs). This highlights the common practice among executives of utilizing a portion of their stock to meet tax liabilities, a detail that underscores the financial planning involved in stock compensation.

Company Information

BridgeBio Pharma, Inc. is incorporated in Delaware and operates under the fiscal year ending on December 31. The company is identified under the SIC classification of Pharmaceutical Preparations, indicating its focus on developing and producing pharmaceutical products.

Reporting Owner's Role

As the Chief Accounting Officer, Apuli Maricel plays a critical role in the financial operations of BridgeBio Pharma, Inc. This position involves overseeing the company's accounting practices, ensuring compliance with financial regulations, and maintaining transparency in financial reporting.

Additional Context

The filing does not include information regarding any future plans for stock transactions by Apuli Maricel or insights into the company's upcoming financial strategies. Additionally, there is no mention of how this transaction may affect the company's stock performance or investor sentiment beyond the immediate implications for Maricel's ownership stake.